Paladin Labs Announces Canadian Launch Of Twinject(R) TwinpackTM For Anaphylaxis

Main Category: Pharmacy / Pharmacist
Article Date: 18 Jun 2009 - 4:00 PDT

email to a friend   printer friendly   opinions  

Good news for the 1.3 million Canadian patients at risk for anaphylaxis, as Paladin Labs Inc. (TSX:PLB), a leading Canadian specialty pharmaceutical company, announced the Canadian launch of Twinject® TwinpackTM, making it more convenient for people to manage this potentially life threatening condition.

Twinject® TwinpackTM includes two Twinject® epinephrine auto-injectors, allowing patients to store an auto-injector in multiple key locations such as home or work, while carrying another device with them at all times. The TwinpackTM also includes a Twinject® demonstrator that helps patients and family members practice using the auto-injector so they feel more confident in an emergency anaphylactic situation.

"It's vital for individuals at risk for anaphylaxis to be prepared for an emergency", says Laurie Harada, Executive Director, Anaphylaxis Canada. This requires having an auto-injector with them at all times and making sure they and others, such as friends, family members, and caregivers, are comfortable using the device. The demonstrator provides an important hands-on teaching tool."

The need for effective anaphylaxis management is clear, with published studies demonstrating that fewer than 30 per cent of patients carry their epinephrine auto-injectors with them at all times(1). In addition, a recent survey shows that 39 per cent to 50 per cent of food-induced anaphylactic reactions in children occurred outside the home(2).

"We are excited to launch the Twinject® TwinpackTM as it addresses the needs of anaphylactic patients. As such, the Twinject® TwinpackTM will provide superior protection for patients and ensure that they are adequately trained and prepared in an anaphylactic situation," said Mark Beaudet, Vice President Sales and Marketing of Paladin Labs.

Twinject® is a novel epinephrine auto-injector indicated for the emergency treatment of severe allergic reactions (anaphylaxis). Twinject® TwinpackTM is available in two dosages (0.3 mg and 0.15 mg) for self-administration.

About Anaphylaxis

Anaphylaxis is a severe, life-threatening systemic allergic reaction triggered by exposure to one or more various antigens, including foods, insect stings, drugs, and latex products. Up to eight percent of children have food allergies, with allergies to peanuts and tree nuts among children having doubled in the past five years. The timing, location, pattern (including onset, severity and length) and specific treatment requirements for each future anaphylactic episode cannot be predicted in advance. It is estimated by Anaphylaxis Canada that there are over 1.3 million Canadians at risk for anaphylaxis.

About Twinject®

Twinject® is a pre-filled, pen size auto-injector with two doses of epinephrine for the emergency treatment of severe allergic reactions (anaphylaxis). The first dose is administered using the auto-injector. The second dose, if needed, is administered via a pre-filled syringe located inside the barrel of the device. Twinject® is available in a compact, crush-resistant carrying case, with instructions for use attached to the device. In addition, a consumer campaign called Twinject® BeReady, is available to provide comprehensive patient training and support. For more information about Twinject®, please visit http://www.twinject.ca.

(1) Goldberg A, Confino-Cohen R. J Allergy Clin Immunol 2000;106(6):1184-1189
(2) Jarvinen KM, et al. J Allergy Clin Immunol 2008;122(1):133-138

Source
Paladin Labs Inc.

• Additional
• References
• Citations